Investment Analysts’ Weekly Ratings Updates for OncoCyte (OCX)

A number of firms have modified their ratings and price targets on shares of OncoCyte (NASDAQ: OCX) recently:

• 10/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/15/2024 – OncoCyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $4.25 price target on the stock.
• 10/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/3/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/27/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/3/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/28/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/22/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

OncoCyte Trading Up 0.3 %

Shares of OCX stock opened at $3.13 on Monday. The firm’s fifty day moving average price is $3.08 and its two-hundred day moving average price is $2.94. OncoCyte Co. has a 1 year low of $2.08 and a 1 year high of $4.34.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The company had revenue of $0.10 million during the quarter.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the acquisition, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrea S. James purchased 33,670 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The disclosure for this purchase can be found here. 1.94% of the stock is owned by corporate insiders.

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.